news
Drug prices in China cut by up to 61 percent for reimbursement scheme list
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
List view / Grid view
Novartis
news
Novartis announces $9.7bn acquisition of The Medicines Company
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
news
First annual Pharmaceutical Invention Index released
The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.
article
Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?
news
Erenumab migraine drug fails to meet NICE recommendation standards
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
news
Cosentyx® (secukinumab) meets clinical trial endpoints
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
news
Scottish Medicines Consortium approves Kymriah® CAR-T therapy
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
news
CEO of Novartis pledges to speed data integrity disclosures
Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
news
NICE recommends voretigene neparvovec for use on NHS
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
news
China’s drug bulk-buy programme has been expanded
China has expanded a pilot drug bulk-buying programme to almost the entire country which is adding pressure on pharma companies.
news
FDA announces expansion of generic impurity investigation
The examination of ARB drugs by the FDA will be extended to include other generics with similar manufacturing processes to identify impurities.
news
Amgen wins court patent ruling over Sandoz biosimilar
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
news
Novartis could face legal action over Zolgensma application
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
news
AstraZeneca and Novartis set to lose out from US drug prices reforms
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
news
First patient enrolled on clinical study for denosumab biosimilar
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
